


I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EL 926058387 US, in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date shown below.

Dated: April 15, 2003 Signature:

(DeAnn F. Smith)



Docket No.: MRI-008A
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Robert Schlegel, *et al.*

Application No.: 09/732560

Group Art Unit: 1631

Filed: December 8, 2000

Examiner: C. Smith

For: COMPOSITION, KITS AND METHODS FOR
IDENTIFICATION, ASSESSMENT,
PREVENTION, AND THERAPY OF
CERVICAL CANCER

#10
Plunkett
5/6/03

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID
SEQUENCE DISCLOSURES AND RESTRICTION REQUIREMENT**

Dear Sir:

This is in response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, mailed from the U.S. Patent and Trademark Office on October 15, 2002. A Request for a Five-Month Extension of Time in which to respond is being filed together with this response. Responsive to the Notice, please amend the above-identified application as follows:

In the Specification:

Please insert after the Abstract, the Sequence Listing submitted herewith, which contains SEQ ID NOS:1-126.

Replace the paragraph at page 27, line 29 through page 28, line 2 of the specification with the following paragraph,

RNA from a source to express the cDNA corresponding to a given tag is first converted to double-stranded cDNA using any standard cDNA protocol. Similar conditions used to generate cDNA for SAGE library construction can be employed except that a modified oligo-dT primer is used to derive the first strand synthesis. For example, the oligonucleotide